Founded in 1989, Ionis Pharmaceuticals is a biotechnology company based in the United States, dedicated to pioneering RNA-targeted drug discovery and development. The company's core mission is to address unmet medical needs through innovative therapies. Ionis focuses on creating drugs that modulate RNA to treat a variety of diseases, including neurological, cardiovascular, and metabolic disorders. Their market focus includes both rare and common diseases, aiming to provide solutions where traditional therapies have failed.
Notable figures associated with Ionis Pharmaceuticals include its founder, Dr. Stanley T. Crooke, a leader in RNA-targeted therapeutics. The company has attracted significant investment from major pharmaceutical firms like Biogen and Roche. Key achievements include the development of Spinraza, the first FDA-approved treatment for spinal muscular atrophy, which has had a profound impact on patients' lives. Ionis's innovative approach has established it as a leader in the biotech industry, contributing substantially to advancements in RNA-based medicine.
